Bob Ings

  • Robert IngsGraduated in biochemistry from the University of Birmingham, UK with a B.Sc. (Hons.) then obtained a Ph.D. while working in industry in conjunction with the London School of Hygiene & Tropical Medicine researching the mode of action of metronidazole in the parasite and host
  • Extensive industrial career covering over 30 years, initially with several European pharmaceutical companies in the UK plus assignments in Italy, Sweden and ultimately the US., most recently as Vice President DMPK, Roche, Palo Alto, CA
  • Experience of working with European, US and Japanese mid to large size pharmaceutical and biotech companies including Pharmacia/Pfizer, Amgen and Daiichi
  • Directed pharmacokinetics and metabolism laboratories of approximately 100 staff supporting both small and large molecule discovery and development
  • Therapeutic areas include oncology, CNS, metabolic disease, inflammation, cardiovascular and anti-infectives, including anti-viral
  • Contributed to 11 global/US and 13 European successful registrations of new medicines
  • Active in the scientific community including past member of the editorial boards or reviewer for Xenobiotica, Biopharm. & Drug Dis., Current Drug Metabolism, J. Pharmacokin. & Biopharm, Eur. J. Clin. Pharm, Brit. J. Clin. Pharm. and J. Pharm. Pharmacol.  Also past Chairperson of the DMDG (UK) and  joint founder of the societies, PK-UK and DMDG (Italy)
  • Authored over 80 publications, including several book chapters, and given over 120 presentations/training courses throughout the world 

    •  

    Selected publications

    1. Ings, R.M.J. McFadzean, J.A. and Ormerod, W.E. (1974)   The mode of action of metronidazole in Trichomonas vaginalis and other microorganisms. Biochem. Pharm., 23,1421-1429.
    2. Ings, R.M.J. and Stevens, L.A. (1983) The pharmacokinetics and metabolism of diuretics in 'Progress in Drug Metabolism' vol 7, Ed. Bridges, J.W. and Chasseaud, L.F., John Wiley & Sons, Chichester, pp 57‑171.
    3. Ings, R.M.J. (1984)   Melanin binding of drugs and its implications. Drug Metab. Rev., 15, 1183 -1212.
    4. Ings, R.M.J. (1984)   Animal studies and the bioavailability testing of drug products in 'Controlled drug bioavailability' vol.2., Ed. Smolen, V.F. and Ball, L., John Wiley and Sons  Inc., New York pp 43 - 89.
    5. Ings, R.M.J., Reeves, D.S., White, L.O., Bax, R.P., Bywater, M.B. and Holt, H.A. (1985).   The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. J. Pharmacokin. Biopharm.,13, 121 - 142.
    6. Campbell D.B. and Ings R.M.J. (1988). New approaches to the use of pharmacokinetics in toxicology and drug development. Human Toxicology, 7, 469-479.
    7. Ings, R.M.J. (1989).  Pharmacokinetics and its application to Drug Development. In 'Xenobiotic Metabolism & Disposition : The Design of Studies on Novel Compounds' Ed Illing, H.P.A., CRC Press Inc, Boca Raton, Florida, pp 99 - 146.
    8. Ings R.M.J. (1990).   Interspecies Scaling and Comparison in Drug Development and Toxicokinetics.    Xenobiotica, Special Issue, 20,1201 ‑ 1231.
    9. Ings, R.M.J. (1994). Pharmacokinetics. In 'Medicinal Chemistry - Principles and Practice' Ed. King, F.D., The Royal Society of Chemistry, Cambridge , UK , pp 67 - 85.
    10. Ings, R.M.J. (1995). Pharmacokinetics: In 'Encyclopedia of Analytical Sciences' Ed. Townsend, A., Academic Press, London , UK , pp 3893 - 3928.
    11. Zhang, J.Y., Zhan, J., Cook, C., Ings, R. and Breau, A.P. (2003). Involvement of human UGT2B7 and 2B15 in rofecoxib metabolism J. Drug Met. & Disp. 31, 652-658.
    12. McLean , M.A., Tam C-Y., Baratta, M.T., Holliman, C.L., Ings, R.M. and Galluppi G.R. (2007). Accelerating Drug Development: Methodogy to support accelerating First-in-Man pharmacokinetic studies by the use of drug candidate microdosing Drug. Dev. Res., 67, 1-9